KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.

Blood Neoplasia · 2026-Aug · PMID 42436879

Panel E质量警告待 EXE 对齐验证

Time to progression from allo-HSCT

Figure 1. Survival endpoints. Similar outcomes in both treatment groups from randomization (A-B) and from time of allografting (C-F). The marks on the plot indicate censoring of individual patients. HR estimates and P values are based on a Cox model adjusted for the stratification factors used at randomization (age and AML type). Allo-HSCT, allogeneic HSCT; N, number of patients.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过否
预期曲线2
实际曲线1
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T16:45:17+00:00